<!doctype html><html lang="en" style="--width: 160px;
        --height: 600px;
        --hcp-disclaimer-font-size: 8px;
        --hcp-disclaimer-top: 0px;
        --hcp-disclaimer-left: 14px;
        --title-font-size: 20px"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,user-scalable=no,initial-scale=1,maximum-scale=1,minimum-scale=1"><meta http-equiv="X-UA-Compatible" content="ie=edge"><title>Ad Banners</title><script src="https://s0.2mdn.net/ads/studio/Enabler.js"></script><script>window.mode = "production";
      // If true, start function. If false, listen for INIT.
      window.onload = function() {
        if (Enabler.isInitialized()) {
          enablerInitHandler();

        } else {
          Enabler.addEventListener(studio.events.StudioEvent.INIT, enablerInitHandler);
        }
      }

      function enablerInitHandler() {

        if (Enabler.isPageLoaded()) {
          politeInit();
        } else {
          Enabler.addEventListener(studio.events.StudioEvent.PAGE_LOADED, politeInit);
        }
        // Start polite loading, or start animation,
        // load in your image assets, call Enabler methods,
        // and/or include other Studio modules.
      }
      function politeInit(){
        // Add your code to hide any loading image or animation and load creative
        // assets or begin creative animation.
      }</script><script defer="defer" src="main.js"></script><link href="main.css" rel="stylesheet"></head><body><div id="container" class="container container-skyscraper"><main id="carousel" data-slide-index="0" style="background-image: url('background.jpg')"><section data-slide-index="0" data-timeout="4000" style="background-color:;"><h2 class="prelude"><span>EVRENZO (roxadustat) is </span><span>indicated for treatment of adult patients with symptomatic </span>anaemia associated with CKD<sup>1</sup></h2><h1 class="title">In anaemia of chronic kidney disease (CKD), the treatment landscape is changing</h1></section><section data-slide-index="1" data-timeout="4000" style="background-color:;"><h1 class="title">Follow a new pathway to treat anaemia of CKD…</h1></section><section data-slide-index="2" data-timeout="4000" style="background-color: #007A33;"><h1 class="title"><span>EVRENZO™</span> harnesses the HIF pathway to stimulate erythropoiesis<sup>1,2</sup></h1><ul><li>HIF (hypoxia-inducible factor) is a central regulator of erythropoiesis<sup>3</sup></li><li>EVRENZO is the first treatment to activate the HIF pathway<sup>4</sup></li><li>Through this action, EVRENZO mimics the body’s natural response to hypoxia<sup>2</sup></li></ul><img src="astellas-logo.svg" alt="Astellas"></section><section data-slide-index="3" data-timeout="3000" style="background-color: #007A33;"><div class="grid"><div class="disclaimer"><p>This advert is intended for UK and EU audience only.</p><p>Please note that indications and availability may vary in different countries.</p><p><span id="bg-exit" class="underline" data-exit-name="Refer to your local summary of product characteristics" data-href="https://www.medicines.org.uk/emc/product/12835" target="_blank" rel="noreferrer">Refer to your local summary of product characteristics/</span>prescribing information for details.</p></div><ol><li>EVRENZO SmPC.</li><li>Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.</li><li>Locatelli F et al. Am J Nephrol. 2017;45:187-199.</li><li>Sanghani NS, Haase VH. Adv Chronic Kidney Dis 2019; 26:253–266.</li></ol><img src="astellas-logo.svg" alt="Astellas"></div></section></main><aside><img src="evrenzo-logo.svg" alt="Evrenzo roxadustat"><div class="legal"><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary" id="bg-exit" data-exit-name="UK Prescribing Information and Adverse" data-href="pi.pdf">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div><small>EVZ_2021_0129_UK OCTOBER 2021</small></div></aside></div></body></html>